A Randomized Trial Comparing Omeprazole, Ranitidine, Cisapride, or Placebo in Helicobacter pylori Negative, Primary Care Patients with Dyspepsia: The CADET-HN Study

Zanten, S. J. O. Veldhuyzen Van; Chiba, Naoki; Armstrong, David; Barkun, Alan N.; Thomson, A. B. R.; Smyth, Sandra; Escobedo, Sergio; Lee, Joanna; Sinclair, Paul

doi:10.1111/j.1572-0241.2005.40280.x

Cited by 105 publications

(101 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Follow up was from 4 to 52 weeks and there was a trend towards PPI being more eff ective than prokinetic therapy (RR=0.78; 0.60-1.02, P =0.06) ( Appendix 2 : Appendix Figure 9 ) but this did not achieve statistical significance. Two trials ( 57,62 ) showed PPI therapy was superior and one ( 66 ) reported no diff erence.…”

Section: Conditional Recommendation Very Low Quality Evidencementioning

confidence: 99%

“…Th ere were no randomized studies comparing prokinetic therapy with placebo. Th ere were three trials ( 57,62,66 ) that compared PPI with prokinetic therapy in 680 dyspepsia patients. Follow up was from 4 to 52 weeks and there was a trend towards PPI being more eff ective than prokinetic therapy (RR=0.78; 0.60-1.02, P =0.06) ( Appendix 2 : Appendix Figure 9 ) but this did not achieve statistical significance.…”

Section: Conditional Recommendation Very Low Quality Evidencementioning

confidence: 99%

See 1 more Smart Citation

ACG and CAG Clinical Guideline: Management of Dyspepsia

Martin

Lacy

Andrews

et al. 2017

American Journal of Gastroenterology

510

520

View full text Add to dashboard Cite

Section: Conditional Recommendation Very Low Quality Evidencementioning

confidence: 99%

Section: Conditional Recommendation Very Low Quality Evidencementioning

confidence: 99%

ACG and CAG Clinical Guideline: Management of Dyspepsia

Martin

Lacy

Andrews

et al. 2017

American Journal of Gastroenterology

510

520

View full text Add to dashboard Cite

“…3 Excessive secretion of gastric acid has been suggested to be involved in the pathogenesis of functional dyspepsia, because proton pump inhibitors are effective for treating dyspepsia in some patients. [4][5][6][7][8][9] However, previous reports regarding the levels of gastric acid secretion in dyspeptic patients showed controversial results. 6,10,11 Furthermore, atrophic gastritis is common in the general population of South Korea and Japan where Helicobacter pylori infection is highly prevalent.…”

Section: Introductionmentioning

confidence: 83%

“…4,5 However, the mechanism underlying this beneficial effect still remains unestablished. Although gastric acid hypersecretion, caused by hypergastrinemia, hyperhistaminemia, or an unknown etiology, may be associated with the effect of proton pump inhibitors, these conditions are not common.…”

Section: Discussionmentioning

confidence: 99%

Association of the Extent of Atrophic Gastritis With Specific Dyspeptic Symptoms

Chung

Lee

Kim

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsIt remains unclear whether atrophic gastritis can affect dyspeptic symptoms. We aimed to investigate whether the extent of atrophic gastritis is associated with specific dyspeptic symptoms. MethodsConsecutive adults in a routine health-checkup program were enrolled in the study. The extent of atrophic gastritis was classified into 3 groups based on the Kimura-Takemoto criteria; the gastritis with no or little atrophy (group A: C0), the gastritis with atrophy mainly in the antrum (group B: C1 and C2), and the gastritis with atrophy in the large area of the corpus (group C: C3 and O). Upper gastrointestinal symptoms were categorized into "typical reflux symptoms," "epigastric pain syndrome (EPS)-related symptoms," and "postprandial distress syndrome (PDS)-related symptoms." ResultsA total of 1827 patients (1009 males, mean age 45.1 years) were included in the analysis. The subgroups of atrophic gastritis were as follows: group A (n = 1218, 66.7%), group B (n = 392, 21.4%), and group C (n = 217, 11.9%). Typical reflux, EPS-related, and PDS-related symptoms were present in 10.5%, 19.8%, and 16.2% of the subjects, respectively. PDS-related and EPS-related symptoms were significantly more prevalent in the group C of male patients and the group B of female patients, respectively, compared with other groups. PDS-related and EPS-related symptoms were independently associated with the group C in males (OR, 2.123; 95% CI, 1.090-4.136) and the group B in females (OR, 2.571; 95% CI, 1.319-5.025), respectively. ConclusionsThe extent of atrophic gastritis appears to affect the generation of specific dyspeptic symptoms in a gender-dependent manner. (J Neurogastroenterol Motil 2015;21:528-536)

show abstract

“…PPIs also showed a certain efficacy on symptom control in patients with FD. Positive results of treatment with a PPI for Helicobacter pylori (H. pylori)-negative dyspepsia has recently been reported in Caucasians; Veldhuyzen van Zanten et al reported that omeprazole was superior to ranitidine, cisapride and placebo [7]. However, it is uncertain whether the Japanese have a similar response because study of PPIs for treatment of upper abdominal symptoms in Japanese population is limited.…”

Section: Introductionmentioning

confidence: 94%

Symptom Diversity of Patients with Reflux Esophagitis: Effect of Omeprazole Treatment

Adachi

Matsumori

Fujisawa

et al. 2006

J. Clin. Biochem. Nutr.

View full text Add to dashboard Cite

Summary Objective: A number of clinical trials have reported that proton-pump inhibitors are efficacious in the treatment of upper abdominal symptoms, but most of these trials have been carried out in Caucasians. This study investigated the type of upper abdominal symptoms reported by Japanese patients with reflux esophagitis and the efficacy of omeprazole for treating their symptoms.Methods: A total of 234 patients aged ≥20 years with grade A to D reflux esophagitis were enrolled in this multicenter, open study. Patients received omeprazole 10 or 20 mg/day for 4 weeks. Symptom and quality of life questionnaires were administered at baseline, week 2 and week 4.Results: Among the 221 evaluable patients, almost 70% reported reflux-type symptoms (e.g. regurgitation and heartburn). Ulcer-and dysmotility-type symptoms (e.g. stomach pain and belching) were also common, occurring in 38-62% of patients. After 4 weeks of omeprazole *To whom correspondence should be addressed. Tel: +81-853-20-2190 Fax: +81-853-20-2187 E-mail: kadachi@med.shimane-u.ac.jp Abbreviations: ARD, acid-related disease; FD, functional dyspepsia; GSRS, Gastrointestinal Symptoms Rating Scale; PPIs, proton pump inhibitors; PU, peptic ulcer; QOL,quality of life; RE, reflux esophagitis; SD, standard deviation. Conclusion: Reflux-type symptoms as well as ulcer-and dysmotility-type symptoms were seen frequently in Japanese patients with reflux esophagitis. However, omeprazole improved all symptom types and quality of life in this patient population.

show abstract

A Randomized Trial Comparing Omeprazole, Ranitidine, Cisapride, or Placebo in Helicobacter pylori Negative, Primary Care Patients with Dyspepsia: The CADET-HN Study

Abstract: Treatment with omeprazole provides superior symptom relief compared to ranitidine, cisapride, and placebo in the treatment of H. pylori negative primary care dyspepsia patients.

Cited by 105 publications

References 29 publications

ACG and CAG Clinical Guideline: Management of Dyspepsia

ACG and CAG Clinical Guideline: Management of Dyspepsia

Association of the Extent of Atrophic Gastritis With Specific Dyspeptic Symptoms

Symptom Diversity of Patients with Reflux Esophagitis: Effect of Omeprazole Treatment

Contact Info

Product

Resources

About